rs7305099 — WNK1 WNK1 intronic variant

WNK1 rs7305099 — Your Kidney's Blood Pressure Thermostat

Blood pressure is ultimately a plumbing problem: the kidneys decide how much salt to keep and how much to excrete, and that decision sets the volume — and thus the pressure — of your blood. At the center of that decision is WNK1, a serine-threonine kinase expressed throughout the kidney's distal nephron that acts as a master switch for renal salt handling¹¹ WNK1, a serine-threonine kinase expressed throughout the kidney's distal nephron that acts as a master switch for renal salt handling
WNK stands for "with no lysine" — the kinase lacks a conserved lysine residue that most kinases use for catalysis, making it structurally unusual. The rs7305099 variant sits within an intron of WNK1 on chromosome 12, tagging a haplotype block that affects WNK1 expression and activity in the kidney. Its G allele is more common globally and is associated with elevated essential hypertension risk, while the minor T allele is protective.

The Mechanism

WNK1 controls blood pressure by regulating the NaCl cotransporter (NCC)²² NaCl cotransporter (NCC)
NCC is the main sodium-chloride transporter in the distal convoluted tubule of the kidney; its activity directly determines how much sodium is reabsorbed versus excreted in urine in the kidney's distal convoluted tubule. Active WNK1 phosphorylates two intermediate kinases — SPAK and OSR1 — which then phosphorylate and activate NCC, increasing sodium reabsorption. More NCC activity means more salt retained, higher blood volume, and higher blood pressure.

The elegant regulatory feature of this system is its potassium-sensing capacity. When dietary potassium is adequate, intracellular chloride rises in distal tubule cells, directly inhibiting WNK1 kinase activity and allowing more sodium to be excreted. When potassium intake is low, chloride falls, WNK1 activates, NCC is phosphorylated, and sodium retention rises — an evolutionary adaptation to potassium-poor environments that becomes hypertension-promoting in modern high-sodium, low-potassium diets.

A rare but instructive clinical example: large intron 1 deletions in WNK1 that increase WNK1 expression cause Gordon's syndrome (pseudohypoaldosteronism type II)³³ Gordon's syndrome (pseudohypoaldosteronism type II)
characterized by hypertension, high potassium, and metabolic acidosis — a naturally occurring experiment showing what too much WNK1 activity does to blood pressure. The rs7305099 variant is not a deletion, but its haplotype-level effects on WNK1 expression likely operate through the same NCC-mediated mechanism at smaller scale.

The Evidence

The direct association evidence for rs7305099 comes from a case-control study in 476 hypertensive and 491 normotensive Northern Han Chinese participants⁴⁴ case-control study in 476 hypertensive and 491 normotensive Northern Han Chinese participants
Liu et al. 2023, Frontiers in Genetics; 12 WNK1 tag SNPs were tested; rs7305099 survived Bonferroni correction. The T allele was significantly protective against essential hypertension: OR 0.627 (95% CI 0.491–0.801; p<0.0002) in the allele model, with homozygous TT carriers showing strikingly lower risk (OR 0.278, 95% CI 0.140–0.552). This is one population study, so the evidence is moderate rather than strong — but it sits within a well-established biological framework where multiple WNK1 variants across independent cohorts consistently associate with blood pressure variation.

Broader WNK1 variant evidence supports the framework: Newhouse et al. 2009⁵⁵ Newhouse et al. 2009
PLoS One; 1,700 hypertensive cases + 1,700 controls in BRIGHT study, replicated in 17,851 participants across 6 populations showed that the WNK1 intron 1 variant rs765250 (in the same gene region) raises systolic BP by 3.14 mmHg (95% CI 1.23–4.9) — a clinically meaningful effect size for a common variant. Tobin et al. 2005⁶⁶ Tobin et al. 2005 demonstrated that WNK1 haplotypes can shift ambulatory blood pressure by >10 mmHg in some carrier groups, and Tobin et al. 2008⁷⁷ Tobin et al. 2008 followed 5,326 children and found WNK1 variants associate with the rate of diastolic blood pressure increase across childhood — suggesting WNK1 variation shapes the developmental trajectory of blood pressure, not just adult phenotype.

Practical Actions

The WNK1-NCC-blood pressure axis has a well-understood dietary leverage point: potassium intake. Because intracellular chloride (which inhibits WNK1) tracks plasma potassium, adequate dietary potassium directly damps WNK1 activity in the distal nephron. For G allele carriers — especially GG homozygotes — who have higher baseline WNK1-NCC activation, ensuring potassium intake reaches the recommended 3,500–4,700 mg daily from food is the most targeted dietary intervention. This is not generic dietary advice: the mechanism is specific to WNK1 biology and operates differently for people with WNK1 risk variants than for those with normal WNK1 function.

Sodium intake amplifies the risk: the WNK1-NCC system is the molecular substrate of salt-sensitive hypertension. Reducing dietary sodium below 2,300 mg daily reduces NCC substrate availability, partially offsetting higher WNK1-driven transporter activity. Monitoring home blood pressure periodically provides an objective measure of whether the WNK1-related sodium retention is expressing in practice.

Interactions

rs7305099 is one of 12 tag SNPs in WNK1 studied by Liu et al.; it is in the same gene region as rs765250 (intron 1) and rs1012729, though their linkage disequilibrium relationships are not fully characterized across populations. The haplotype A-A-A-C-G-G-G identified in the same study was associated with increased hypertension susceptibility (OR 1.23, p=0.043), suggesting rs7305099 may be part of a broader hypertension-risk haplotype.

WNK1 variants interact biologically with potassium intake (via the chloride-sensing mechanism) and with sodium intake (salt sensitivity). No specific compound genotype interaction with another GeneOps SNP has been published, but the AGT (angiotensinogen) variants rs699 and rs4762, also in the renin-angiotensin system, operate on the same blood pressure output and may compound with WNK1 variation in individuals with multiple risk alleles across these pathways.